Disclosures for "Non-motor Effects of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study"
-
Dr. Sarva has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Sarva has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Sarva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Dr. Sarva has received research support from Insightec. The institution of Dr. Sarva has received research support from NeuroNext. The institution of Dr. Sarva has received research support from Neuroderm. The institution of Dr. Sarva has received research support from Covance. The institution of Dr. Sarva has received research support from Prevail. The institution of Dr. Sarva has received research support from Bluerock Therapeutics. The institution of Dr. Sarva has received research support from Biogen. The institution of Dr. Sarva has received research support from Roche. The institution of Dr. Sarva has received research support from National Institute of Aging. The institution of Dr. Sarva has received research support from Michael J Fox Foundation. The institution of Dr. Sarva has received research support from Novo Nordisk. Dr. Sarva has received research support from Bukwang. The institution of Dr. Sarva has received research support from Bial.
-
Dr. Henchcliffe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer. Dr. Henchcliffe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AskBio. Dr. Henchcliffe has received personal compensation in the range of $0-$499 for serving as a Consultant for Certara. Dr. Henchcliffe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Meira GTx. Dr. Henchcliffe has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ProJenX. Dr. Henchcliffe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Canary Global Inc . Dr. Henchcliffe has stock in Axent Biosciences Inc. The institution of Dr. Henchcliffe has received research support from Weston Brain Institute. The institution of Dr. Henchcliffe has received research support from Blue Rock Therapeutics.
-
Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Insightec. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Lozano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Functional Neuromodulation.
-
Suneil Kalia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Suneil Kalia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NovaNordisk. Suneil Kalia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Suneil Kalia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medtronic. Suneil Kalia has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Abbott. Suneil Kalia has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Boston. The institution of Suneil Kalia has received research support from CIHR. The institution of Suneil Kalia has received research support from MJFF. The institution of Suneil Kalia has received research support from Parkinson Canada. The institution of Suneil Kalia has received research support from Weston Foundation. Suneil Kalia has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Yu has nothing to disclose.
-
Cameron Brennan has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. York has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for RAD-PD. The institution of Dr. York has received research support from Michael J. Fox Foundation. The institution of Dr. York has received research support from NIH. The institution of Dr. York has received research support from Takeda.
-
Mrs. Stemple has nothing to disclose.
-
Dr. Abid has received personal compensation for serving as an employee of BlueRock Therapeutics.
-
Dr. Yountz has received personal compensation for serving as an employee of Alexion, AstraZeneca Rare Disease. Dr. Yountz has stock in AstraZeneca.
-
Dr. Enayetallah has received personal compensation for serving as an employee of Alexion. Dr. Enayetallah has received stock or an ownership interest from Alexion. Dr. Enayetallah has received stock or an ownership interest from AstraZeneca.
-
Mr. Lampron has received personal compensation for serving as an employee of Bluerock Therapeutics. Mr. Lampron has received personal compensation for serving as an employee of Alexion Inc..
-
Viviane Tabar has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BLueRock Therapeutics. An immediate family member of Viviane Tabar has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BLueRock Therapeutics. The institution of Viviane Tabar has received research support from BLueRock Therapeutics. The institution of an immediate family member of Viviane Tabar has received research support from BLueRock Therapeutics. An immediate family member of Viviane Tabar has received intellectual property interests from a discovery or technology relating to health care. Viviane Tabar has received intellectual property interests from a discovery or technology relating to health care.